Wintac is currently trading at Rs. 268.00, up by 1.00 points or 0.37% from its previous closing of Rs. 267.00 on the BSE.
The scrip opened at Rs. 267.00 and has touched a high and low of Rs. 268.00 and Rs. 267.00 respectively. So far 4744 shares were traded on the counter.
The BSE group 'XT' stock of face value Rs. 10 has touched a 52 week high of Rs. 268.00 on 24-Jul-2017 and a 52 week low of Rs. 130.00 on 15-Nov-2016.
Last one week high and low of the scrip stood at Rs. 268.00 and Rs. 251.00 respectively. The current market cap of the company is Rs. 268.65 crore.
The promoters holding in the company stood at 54.99%, while Institutions and Non-Institutions held 0.01% and 45.00% respectively.
Wintac has received an approval for issue of 66.83 lakh equity shares on Rights basis to the existing shareholders of the company in the ratio of 3 : 2 i.e., 2 (two) shares for every 3 (three) shares held at a price of Rs 100 per share (Rs10 face value + Rs 90 premium per share) aggregating to Rs 66.83 crore.
The funds raised would be utilised to meet the capital expenditure on construction of New Manufacturing Facility and other corporate funds requirements and also to augment the long term working capital of the company. The board of directors at their meeting held on July 27, 2017, has approved for the same.
Wintac’s range of specialties includes Antifungal, Anticancer, Cardiovascular, Corticosterid , Antiemetic, Large and small volume injectable and Ophthalmic solutions. The company has also forayed into the field of critical care by manufacturing and marketing products targeted to the critically ill patients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: